Americans Reject Cannabis Danger Narrative, New Poll Shows

Poll Shows Clear Majority View Cannabis as Low-Risk

Most Americans reject the premise that cannabis poses significant health or social dangers, according to the survey. Exact percentages weren't disclosed in the initial release, but the poll's framing signals a threshold shift. Voters no longer treat cannabis as a Schedule I substance meriting federal prohibition. That's a problem for the DEA, which continues to classify cannabis alongside heroin despite mounting evidence and state-level liberalization.

This isn't incremental movement. It's a wholesale rejection of the Controlled Substances Act's foundational premise.

Federal Policy Lags Voter Consensus by Years

The gap between public opinion and federal law has never been wider. Thirty-eight states have legalized medical or adult-use cannabis, yet the DEA's ongoing rulemaking on rescheduling treats the plant as a live policy debate rather than a settled question. It's now in its third year. The poll data suggests voters moved on from that debate years ago.

Congress has similarly stalled. The SAFER Banking Act remains in limbo despite bipartisan support, and comprehensive reform bills like the Cannabis Administration and Opportunity Act haven't advanced past committee. 280E tax penalties continue to drain MSO cash flow, and interstate commerce remains illegal even between states with identical legalization frameworks.

State-Level Momentum Continues Unabated

Voter sentiment has translated into ballot-box wins across red and blue states alike. In 2024, Florida, South Dakota, and Arkansas all saw legalization measures pass with margins exceeding 55 percent. Ohio's adult-use program launched in January 2026. It cleared $200 million in sales within six months. Pennsylvania is expected to vote on legalization in November 2026, with polling showing 62 percent support.

For full background on this story, see the CannIntel topic hub on Cannabis Public Opinion Polling.

MSO Investor Thesis Strengthens on Sentiment Shift

Public opinion data matters because it drives state ballot measures, which drive MSO revenue growth. Curaleaf, Trulieve, Green Thumb Industries, and Verano all derive the majority of their revenue from limited-license states where voter-approved legalization created moat-protected markets. Each new state that flips adds $500 million to $1.5 billion in addressable market within 18 months of launch. Pennsylvania, Wisconsin, Kentucky—they're all in play.

The thesis is simple: if voters don't think cannabis is dangerous, they vote yes on legalization. If they vote yes, MSOs expand. The poll data suggests that tailwind isn't slowing.

The disconnect between federal prohibition and voter sentiment creates a rare arbitrage window for operators who can navigate state-by-state expansion without waiting for Congress.

Perception Shift Pressures Federal Agencies

The DEA and FDA face mounting political risk as public opinion moves decisively against their regulatory posture. The DEA's proposed rescheduling of cannabis to Schedule III was announced in May 2024 and is still pending final rule. It was already seen as a half-measure. Now, with polling showing voters don't view cannabis as dangerous at all, Schedule III looks like bureaucratic theater rather than evidence-based policy.

The FDA's continued refusal to approve cannabis as a drug also sits awkwardly against voter sentiment. If the public doesn't see risk, the FDA's "insufficient evidence" standard starts to look like obstruction rather than prudence.

Demographic Breakdowns Point to Generational Lock-In

The poll didn't release full demographic crosstabs, but past surveys show the perception shift is most pronounced among voters under 50. Pew Research data from 2025 found 71 percent of adults aged 18-34 support legalization, compared to 52 percent of those over 65. That gap suggests the pro-legalization majority will only grow as older cohorts age out of the electorate.

The implication? Even if federal reform stalls through 2028, state-level momentum is demographically locked in for the next decade.

What Happens When Voters Stop Seeing Risk

The most immediate consequence of this sentiment shift is ballot-measure success rates approaching 60-65 percent in swing states. That's the threshold where legalization becomes a fait accompli regardless of legislative gridlock. Pennsylvania, Wisconsin, and Kentucky are all watching Florida's 2024 adult-use launch and drawing the obvious conclusion. First-year sales hit $1.2 billion.

The second-order effect is harder to model but potentially more significant: once voters stop seeing cannabis as dangerous, they start asking why their tax dollars fund enforcement. That's when prohibition becomes a budget question, not a moral one. Budget questions get resolved faster.

The next signal to watch: Pennsylvania's November ballot measure. If it clears 60 percent—and current polling suggests it will—the Eastern Seaboard will have effectively legalized from Maine to Florida, leaving federal prohibition as a Midwest and Deep South anomaly. At that point, the poll data won't matter. The map will speak for itself.